Background: Shivering is a common postanesthesia adverse event with multiple etiologies. At present tramadol is a widely used drug for the control of shivering. However, tramadol may cause a lot of nausea and vomiting. Hence, the need to find a better drug with less of side effects. The aim of this study was to compare the efficacy of dexmedetomidine and tramadol in the treatment of post-spinal anesthesia (SA) shivering as well as to compare their side-effect profile.

Materials And Methods: This prospective, double-blind, randomized controlled trial was conducted in a tertiary care hospital. A total of 100 patients having shivering after SA were enrolled, out of which fifty received dexmedetomidine (Group A) and 50 received tramadol (Group B). The response rate, time to cessation of shivering and side effects (if any) was noted. All the results were analyzed using Student's -test and Chi-square test.

Results: All patients who received dexmedetomidine as well as tramadol had cessation of shivering. The time to cessation of shivering was significantly less with dexmedetomidine (174.12 ± 14.366 s) than with tramadol (277.06 ± 23.374 s) ( < 0.001). The recurrence rate of shivering with dexmedetomidine was less (6%) as compared to tramadol (16%). Nausea and vomiting was found to be higher in the case of tramadol. On the other hand, dexmedetomidine caused moderate sedation (modified Ramsay sedation score = 3-4) from which the patient could be easily awoken up.

Conclusion: Dexmedetomidine offers better results than tramadol with fewer side effects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292846PMC
http://dx.doi.org/10.4103/1658-354X.197344DOI Listing

Publication Analysis

Top Keywords

side effects
12
cessation shivering
12
tramadol
10
shivering
9
dexmedetomidine
8
efficacy dexmedetomidine
8
dexmedetomidine tramadol
8
post-spinal anesthesia
8
anesthesia shivering
8
nausea vomiting
8

Similar Publications

Tear trough deformity (TTD) is a significant cosmetic concern, with current treatments relying primarily on invasive injectable fillers, which are costly and carry risks of complications. Despite the widespread use of hyaluronic acid (HA) in cosmetic applications, its poor dermal permeation has limited the development of effective topical fillers for TTD.This study aim to develop and evaluate a novel hyaluronic acid nanogel (nanofiller, NF) as a non-invasive topical filler for TTD.

View Article and Find Full Text PDF

Understanding hepcidin for iron management in pregnancy.

Transfus Med

January 2025

SUWON (Surgery, Oncology and Womens), Department of Haematology, University of Oxford, Oxford, UK.

Iron deficiency anaemia (IDA) poses a significant health challenge during pregnancy, affecting up to 30% of pregnant women in the UK. It has been linked to poor health outcomes for the mother, foetus, and the infant. Despite its prevalence and impact, current diagnostic and therapeutic approaches are limited.

View Article and Find Full Text PDF

Background/purpose: Autologous dentin materials are among the most promising bone substitutes for preventing osseous defects on the distal side of the lower second molar. This study aimed to investigate the effects of autologous demineralized dentin matrix on postoperative complications and wound healing after lower third molar surgery.

Materials And Methods: Thirteen patients with bilateral symmetrical lower third molars participated in this split-mouth randomized clinical trial.

View Article and Find Full Text PDF

Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy.

Life Metab

December 2024

State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an, Shaanxi 710032, China.

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases and is mainly caused by metabolic disorders and systemic inflammatory responses. Recent studies have indicated that the activation of the mammalian (or mechanistic) target of rapamycin (mTOR) signaling participates in MASH progression by facilitating lipogenesis and regulating the immune microenvironment. Although several molecular medicines have been demonstrated to inhibit the phosphorylation or activation of mTOR, their poor specificity and side effects limit their clinical application in MASH treatment.

View Article and Find Full Text PDF

Background: Injuries to the common peroneal nerve often result in significant sensory and motor function loss, severely affecting patients' quality of life. Although existing treatments, including medication and surgery, provide some degree of efficacy, their effectiveness is limited by factors such as tolerance and adverse side effects.

Methods: This study aims to evaluate the effects of a 4-week regimen of mirror therapy combined with neuromuscular electrical stimulation on lower limb function, muscle strength, and sensation in patients with common peroneal nerve injuries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!